Appeal details - Trastuzumab as adjuvant therapy for early stage breast cancer

The Institute has received one appeal from Newbury and Community Primary Care Trust against the Final Appraisal Determination and Guidance on this technology.

As set out in the Guidance for Appellants members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing. The number of observers admitted to the hearing will be limited to a number appropriate for the venue, and priority will be given to members of the public who are not employed by the appellant..

A hearing will be held on at NICE (Midcity Place, 71 High Holborn, WC1V 6NA) on Wednesday 26 July starting at 09.30am..

The registration period to apply to attend the appeal has now passed. Journalists wishing to attend the appeal should contact the NICE press office direct..